Company Analysis - Mergers & Acquisitions
An eye to the future
The healthcare industry is undoubtedly undergoing a significant change in the way it does business. New biotechnologies and advances in the life sciences, as well as new approaches to treating disease particularly with regards to personalised and patient specific therapeutics, are forcing pharmaceutical companies to adapt. Companies have responded by streamlining business models, re-evaluating the value of core and peripheral assets, and refocusing on key and upcoming therapeutic areas.
This shift is reflected in the M&A that are either underway or planned for the future. There is an air of caution now, which is guiding companies to make carefully considered decisions focused entirely on the quintessentials of pipelines, to guarantee ongoing and future success with a steady production of saleable drugs in the most relevant, niche or emerging markets. The glory days of huge unrivalled blockbusters and vast mergers may well be over, but a new and perhaps far more exciting future is on the horizon.
Alix Biancardi
Pharmaprojects Analyst
Photograph courtesy of *g.a.p*
